| Title: | Quantitative imaging biomarkers of immune-related adverse events in immune-checkpoint blockade-treated metastatic melanoma patients : a pilot study |
|---|
| Authors: | ID Hribernik, Nežka (Author)
ID Huff, Daniel T. (Author)
ID Studen, Andrej (Author)
ID Zevnik, Katarina (Author)
ID Klaneček, Žan (Author)
ID Emamekhoo, Hamid (Author)
ID Škalič, Katja (Author)
ID Jeraj, Robert (Author)
ID Reberšek, Martina (Author) |
|---|
| Files: |  PDF - Presentation file, download (9,65 MB)
MD5: 8A73C7F3392A0EB3317C8F0D91B00005
|
|---|
| Language: | English |
|---|
| Typology: | 1.01 - Original Scientific Article |
|---|
| Organization: |  OI - Institute of Oncology
|
|---|
| Abstract: | Purpose: To develop quantitative molecular imaging biomarkers of immune-related adverse event (irAE) development in malignant melanoma (MM) patients receiving immune-checkpoint inhibitors (ICI) imaged with 18F-FDG PET/CT. Methods: 18F-FDG PET/CT images of 58 MM patients treated with anti-PD-1 or anti-CTLA-4 ICI were retrospectively analyzed for indication of irAE. Three target organs, most commonly affected by irAE, were considered: bowel, lung, and thyroid. Patient charts were reviewed to identify which patients experienced irAE, irAE grade, and time to irAE diagnosis. Target organs were segmented using a convolutional neural network (CNN), and novel quantitative imaging biomarkers - SUV percentiles (SUVX%) of 18F-FDG uptake within the target organs - were correlated with the clinical irAE status. Area under the receiver-operating characteristic curve (AUROC) was used to quantify irAE detection performance. Patients who did not experience irAE were used to establish normal ranges for target organ 18F-FDG uptake. Results: A total of 31% (18/58) patients experienced irAE in the three target organs: bowel (n=6), lung (n=5), and thyroid (n=9). Optimal percentiles for identifying irAE were bowel (SUV95%, AUROC=0.79), lung (SUV95%, AUROC=0.98), and thyroid (SUV75%, AUROC=0.88). Optimal cut-offs for irAE detection were bowel (SUV95%>2.7 g/mL), lung (SUV95%>1.7 g/mL), and thyroid (SUV75%>2.1 g/mL). Normal ranges (95% confidence interval) for the SUV percentiles in patients without irAE were bowel [1.74, 2.86 g/mL], lung [0.73, 1.46 g/mL], and thyroid [0.86, 1.99 g/mL]. Conclusions: Increased 18F-FDG uptake within irAE-affected organs provides predictive information about the development of irAE in MM patients receiving ICI and represents a potential quantitative imaging biomarker for irAE. Some irAE can be detected on 18F-FDG PET/CT well before clinical symptoms appear. |
|---|
| Keywords: | melanoma, malignant melanoma, immune-checkpoint inhibitors, molecular imaging biomarkers |
|---|
| Publication status: | Published |
|---|
| Publication version: | Version of Record |
|---|
| Publication date: | 27.12.2021 |
|---|
| Publisher: | Springer Nature |
|---|
| Year of publishing: | 2022 |
|---|
| Number of pages: | str. [1-10] |
|---|
| Numbering: | Vol. , no. |
|---|
| PID: | 20.500.12556/DiRROS-15457  |
|---|
| UDC: | 616.5 |
|---|
| ISSN on article: | 1619-7070 |
|---|
| DOI: | 10.1007/s00259-021-05650-3 |
|---|
| COBISS.SI-ID: | 91868163 |
|---|
| Copyright: | by Authors |
|---|
| Publication date in DiRROS: | 07.09.2022 |
|---|
| Views: | 498 |
|---|
| Downloads: | 146 |
|---|
| Metadata: |     |
|---|
|
:
|
Copy citation |
|---|
| | | | Share: |  |
|---|
Hover the mouse pointer over a document title to show the abstract or click
on the title to get all document metadata. |
